Sobrevida en pacientes con diagnóstico de cáncer de mama sujetos a terapia neoadyuvante en Solca desde enero 2016 a diciembre 2021.

Abstract

Breast cancer is the main type of cancer diagnosed in women following skin cancers and remains the second leading cause of mortality globally. Objective: To determine survival in patients diagnosed with breast cancer subjected to neoadjuvant therapy from January 2016 to December 2021. Methodology: Observational, retrospective, crosssectional and analytical study in patients who were admitted to the oncology department of SOLCA Hospital in 2016-2021. Results: A survival rate of 87.1% was determined (n=356). The stages IA and IB obtained the highest survival percentages (≥ 91.17%) and the stages IIIA, IIIB, and IIIC (≥ 89.5%) being statistically significant (p=0.0). Conclusion: The use of neoadjuvant therapy in the treatment of breast cancer, used both in combination with the adjuvant or individually, has an impact in the prognosis of the disease with success rates of 87.01% in this study. Recommendations: Carrying out further prospective experimental studies analyzing the impact of neoadjuvant therapies during the initial stages of disease may prove relevant in subsequent initial treatment schemes.